4//SEC Filing
Rosenberg Noah L. 4
Accession 0001209191-21-007031
CIK 0001438533other
Filed
Feb 1, 7:00 PM ET
Accepted
Feb 2, 9:31 PM ET
Size
9.2 KB
Accession
0001209191-21-007031
Insider Transaction Report
Form 4
Rosenberg Noah L.
Chief Medical Officer
Transactions
- Sale
Common Stock
2021-02-02$30.75/sh−1,250$38,438→ 46,470 total - Award
Common Stock
2021-01-31+5,000→ 47,720 total - Sale
Common Stock
2021-02-02$30.75/sh−563$17,312→ 45,907 total
Footnotes (3)
- [F1]On January 31, 2020, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 10,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. On January 31, 2021, a portion of the PRSUs vested upon the 12 month anniversary of the date of grant, following the Issuer's prior confirmation of the satisfaction of a performance criterion related to the full enrollment of the DUPLEX study.
- [F2]The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.
- [F3]The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.
Documents
Issuer
Travere Therapeutics, Inc.
CIK 0001438533
Entity typeother
Related Parties
1- filerCIK 0001579649
Filing Metadata
- Form type
- 4
- Filed
- Feb 1, 7:00 PM ET
- Accepted
- Feb 2, 9:31 PM ET
- Size
- 9.2 KB